Cytokinetics Myqorzo Launch Shows Early Patient Adoption but Revenue Per Patient Raises Questions

What happened

Cytokinetics' first quarter since Myqorzo's launch delivered 680 patients prescribed by 275 HCPs in a partial quarter, generating $4.8M in net product revenues, while ACACIA-HCM met dual primary endpoints and EU approval was granted. However, the modest revenue relative to patient count suggests many patients may still be on free drug or bridge programs, implying weaker-than-expected early payer conversion. The ACACIA success is positive but was largely anticipated, and the balance sheet remains strained with $1.1B cash against heavy obligations. Camzyos' entrenched position and similar REMS profile continue to pressure Myqorzo's differentiation, making sustained share gains uncertain. Early launch metrics provide some validation but do not yet confirm the high-growth trajectory priced into the stock.

Implication

For investors, the Q1 results offer a mixed signal: prescription uptake validates clinical demand, but the $4.8M revenue on 680 patients implies an annualized run rate well below the $120M base-case assumption for 2026, especially if free-drug programs persist. ACACIA-HCM success removes one risk but was already discounted. The stock's ~$63 price still embeds aggressive assumptions that may not materialize if net pricing disappoints. We recommend trimming on strength and awaiting Q2 data for evidence of sustainable revenue per patient before committing new capital. The thesis hinges on whether Myqorzo can convert early adopters into durable, high-margin revenue while competing against an entrenched Camzyos. Any signs of slower payer coverage or rising free-drug usage would reinforce the bear case.

Thesis delta

The launch data provides early proof of patient interest but introduces a new concern: revenue per patient appears low, suggesting challenges in converting prescriptions to paid therapy. This tempers the bullish narrative and delays the expected revenue inflection. While ACACIA-HCM success expands the pipeline, the core oHCM launch must demonstrate strong net revenue trajectory to support the current valuation. The thesis shifts from 'unproven but promising' to 'validated adoption but questionable monetization,' increasing the likelihood of downside if revenue fails to accelerate in Q2.